An international team of scientists, including researchers at Columbia University Medical Center (CUMC), has identified a key metabolic enzyme that common malaria parasites require for survival at each stage of infection in humans.
These are malaria parasites (labeled with flourescent protein) in the late stages of development, superimposed on a field of red blood cells. The many nuclei of the parasites' daughter cells are labeled in blue, and the plasma membranes surrounding the daughter cells are labeled in green. Imidazopyrazine treatment disrupts formation of the membranes around the daughter cells.
Credit: Marcus C.S. Lee, Ph.D./Columbia University Medical Center
The findings raise the possibility of a new approach to combating malaria, one of the world's deadliest diseases. The study was published today in the online edition of the journal Nature.
"Perhaps the most exciting aspect of our findings is that this enzyme is required at all stages of the parasites' life cycle in humans," said co-first author Marcus C.S. Lee, PhD, associate research scientist in microbiology & immunology at CUMC.
"This is important because most antimalarials are effective at killing the parasites only as they circulate in the bloodstream. However, the parasites can hide in the liver for years before reemerging and triggering a relapse of the disease. By identifying this enzyme, we may be able to develop a new way to kill the parasites in their dormant stage."
The other co-first author is Case W. McNamara, PhD, research investigator at the Genomics Institute for the Novartis Research Foundation. The study leaders are Elizabeth A. Winzeler, PhD, professor of pharmacology and drug discovery at University of California San Diego, and Thierry Diagana, head of Novartis Institute for Tropical Diseases in Singapore.
The enzyme — phosphatidylinositol 4-kinase (PI4K) — was found by screening more than a million drug compounds against Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. Using this screen, the researchers found a class of compounds known as imidazopyrazines, which are capable of killing several species of Plasmodium at each stage of the parasites' life cycle in its vertebrate host. Also important, the compounds had no effect on human cells.
The researchers identified the target of the imidazopyrazines by evolving parasite cell lines that were resistant against the drugs and then analyzing the parasites' genomes for the changes responsible for conferring resistance. Those genetic changes pointed to the gene that encodes PI4K.
The CUMC team, led by David Fidock, PhD, professor of microbiology & immunology and medical sciences (in medicine), used novel genetic tools to confirm that PI4K was being directly targeted by the imidazopyrazines.
Then, using cellular imaging, the CUMC team found that imidazopyrazines interfere with the function of PI4K on the parasite Golgi (the organelle that packages proteins for delivery to other cellular destinations). "We think that disrupting the function of PI4K at the Golgi stops the parasite from making new membranes around its daughter cells, thereby preventing the organism from reproducing," said Dr. Lee.
Because PI4K is also found in humans, Dr. Winzeler said, the next challenge is to develop a drug that retains selectivity between the parasite and human versions of the enzyme. "As we now know the identity of this protein and hope to soon solve its structure, this task should be much easier," she said.
The paper is titled, "Targeting Plasmodium phosphatidylinositol 4-kinase to eliminate malaria." The other contributors are: Chek Shik Lim (Novartis Institutes for Tropical Disease, Singapore), Siau Hoi Lim (Novartis), Jason Roland (UCSD), Advait Nagle (UCSD), Oliver Simon (Novartis), Bryan K.S. Yeung (Novartis), Arnab K. Chatterjee (UCSD), Susan L. McCormack (UCSD), Micah J. Manary (UCSD), Anne-Marie Zeeman (Biomedical Primate Research Centre, Rijswijk, the Netherlands), Koen J. Dechering (TropIQ Health Sciences, Nijmegen, the Netherlands), T.R. Santha Kumar (CUMC), Philipp P. Henrich (CUMC), Kerstin Gagaring (UCSD), Maureen Ibanez (UCSD), Nobutaka Kato (UCSD), Kelli L. Kuhen (UCSD), Christoph Fischli (Swiss Tropical and Public Health Institute, Basel, Switzerland), Matthias Rottmann (Swiss Tropical and Public Health Institute and University of Basel, Basel, Switzerland), David M. Plouffe (UCSD), Badry Bursulaya (UCSD), Stephan Meister UCSD), Lucia Rameh (Boston University, Boston), Joerg Trappe (Novartis Institutes for BioMedical Research, Basel, Switzerland), Dorothea Haasen (Novartis, Basel, Switzerland), Martijn Timmerman (TropIQ Health Sciences), Robert W. Sauerwein (Trop IQ Health Sciences and Radboud University, Nijmegen Medical Centre, Nijmegen, the Netherlands), Rossarin Suwanarusk (Agency for Science Technology and Research, Biopolis, Singapore), Bruce Russell (Agency for Science Technology and Research and National University of Singapore, National University Health System, Singapore), Laurent Renia (Agency for Science Technology and Research), Francois Nosten (University of Oxford, Oxford, UK, and Mahidol University, Mae Sot, Thailand), David C. Tully (UCSD), Clemens HM Kocken (Biomedical Primate Research Centre), Richard J. Glynne (UCSD), Christophe Bodenreider (Novartis, Singapore), and Thierry T. Diagana (Norvartis, Singapore).
The authors wish to disclose the following, which may be considered a conflict of interest: C.W.M, C.S.L, S.H.L, J.R., O.S., B.K.S.Y., K.L.K., K.G., D.M.P., B.B., J.T., D.H., D.T., R.J.G., C.B. and T.T.D. are employed by Novartis. C.W.M, J.R., K.L.K., B.B., J.T., D.H., D.T., R.J.G, T.T.D. and E.A.W. own shares of Novartis AG stock. E.A.W. has received grants from Novartis.
The study was supported by grants from the Wellcome Trust (WT078285 and WT096157) and funding from the Medicines for Malaria Venture at the Genomics Institute of the Novartis Research Foundation, the Swiss Tropical and Public Health Institute, Columbia University, the Novartis Institute for Tropical Diseases, the Singapore Immunology Network and Horizontal Programme on Infectious Diseases under the Agency Science Technology and Research, and the Wellcome Trust (UK). SMRU is sponsored by the Wellcome Trust of Great Britain, as part of the Oxford Tropical Medicine Research Programme of Wellcome Trust-Mahidol University. E.A.W. and D.A.F. are supported by grants from the Bill and Melinda Gates Foundation, MMV, and the NIH (R01AI090141 to E.A.W. and R01085584 and R01079709 to D.A.F.).
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.
Karin Eskenazi | EurekAlert!
Switch-in-a-cell electrifies life
18.12.2018 | Rice University
Plant biologists identify mechanism behind transition from insect to wind pollination
18.12.2018 | University of Toronto
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
18.12.2018 | Materials Sciences
18.12.2018 | Physics and Astronomy
18.12.2018 | Physics and Astronomy